|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Kiromic Biopharma, Inc. (KRBP) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
7,330,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Kiromic BioPharma is an artificial intelligence driven, end-to-end Chimeric Antigen Receptor T cell (CAR-T cell) and gene therapy company, developing the multi-indication allogeneic CAR-T cell therapy, that exploits the natural potency of the Gamma Delta T cell to target solid tumors. Co. develops its brand of CAR-T cell product candidates known as ALEXIS. The product candidates are: ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. These are designed to treat cancer by capitalizing on the immune system's ability to destroy cancer cells.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mirandola Leonardo |
CSOOfficer |
• – – |
2024-05-03 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
56,926 |
|
- |
|
| Bersani Pietro |
CEO |
• • – |
2024-05-03 |
4 |
A |
$0.00 |
$0 |
D/D |
45,968 |
45,968 |
|
- |
|
| Hungerford Brian |
CFO |
• – – |
2024-05-03 |
4 |
A |
$0.00 |
$0 |
D/D |
56,933 |
56,933 |
|
- |
|
| Misajon Pamela |
Director |
– • – |
2024-03-18 |
4 |
A |
$0.00 |
$0 |
D/D |
18,000 |
25,500 |
|
- |
|
| Nagel Michael |
Director |
– • – |
2024-03-18 |
4 |
A |
$0.00 |
$0 |
D/D |
18,000 |
42,296 |
|
- |
|
| Catlin Michael |
Director |
– • – |
2024-03-18 |
4 |
A |
$0.00 |
$0 |
D/D |
18,000 |
25,500 |
|
- |
|
| Clark Daniel Grant |
Chief Financial Officer |
• – – |
2022-08-11 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
62,770 |
|
- |
|
| Dahlbeck Scott |
Chief of Staff |
• – – |
2022-08-11 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
496,757 |
|
- |
|
| Bersani Pietro |
Chief Executive Officer |
• • – |
2022-08-11 |
4 |
A |
$0.00 |
$0 |
D/D |
638,298 |
638,298 |
|
- |
|
| Dahlbeck Scott |
Chief Medical Officer |
• – – |
2022-05-23 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,240 |
446,757 |
|
- |
|
| Clark Daniel Grant |
Interim CFOOfficer |
• – – |
2021-09-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
29,516 |
|
- |
|
| Clark Daniel Grant |
Interim CFOOfficer |
• – – |
2021-09-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
6,866 |
|
- |
|
| Chiriva Internati Maurizio |
CHIEF EXECUTIVE OFFICER |
• • – |
2021-09-09 |
4 |
B |
$3.70 |
$10,357 |
D/D |
2,800 |
1,378,072 |
2.81 |
- |
|
| Ryan Michael Charles |
See Remarks |
• – – |
2021-07-13 |
4 |
A |
$0.00 |
$0 |
D/D |
50,189 |
50,189 |
|
- |
|
| Schneider Jerry A. |
Director |
– • – |
2021-05-24 |
4 |
B |
$7.31 |
$36,550 |
D/D |
5,000 |
5,000 |
2.39 |
- |
|
| Tontat Tony |
CFOOfficer |
• • – |
2020-10-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
402,000 |
|
- |
|
| Dahlbeck Scott |
Chief Medical OfficerOfficer |
• – – |
2020-10-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
429,517 |
|
- |
|
| Chiriva Internati Maurizio |
Chairman, CEO, and PresidentOf |
• • – |
2020-10-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,375,272 |
|
- |
|
| Rotino Gianluca |
CSIOOfficer |
• • – |
2020-10-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
320,000 |
|
- |
|
19 Records found
|
1
|
Page 1 of 1 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
